Cerebrospinal fluid levels of catecholamine metabolites in Parkinson’s disease and L-DOPA-induced dyskinesia

Bidragets oversatte titel: Katekolamin-metabolit-niveauet i rygmarvsvæsken ved Parkinson's sygdom og L-DOPA-induceret dyskinesi.

Andreas Dammann Andersen, Michael Binzer, Egon Stenager, Morten Blaabjerg, Jesper Foged Havelund, Nils J. Færgeman, Jan Bert Gramsbergen

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskning

Resumé

Levodopa (L-DOPA) is effective in the symptomatic treatment of Parkinson’s disease (PD), but chronic use is associated with L-DOPA-induced dyskinesia (LID). In the 6-hydroxydopamine rat model of PD, L-DOPA treatment increases dopamine, its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), as well as 3-O-methyl-DOPA (3-OMD) and tyrosine in the striatum. These changes are most pronounced in dyskinetic rats .(Poster Jesper Christensen, FENS-3253).
Aim:
Investigating whether tyrosine/dopamine and tryptophan/kynurenine metabolites are altered in LID compared to non-dyskinetic PD patients and controls.
Method:
Cerebrospinal fluid (CSF) of 6 age-matched controls and 16 PD patients, (11 receiving levodopa, 6 dyskinetic and 6 not receiving levodopa), was analysed for catecholamines and metabolites by HPLC with electrochemical detection. Samples were collected after overnight fasting and 1 hour after intake of medication.
Results and conclusion:
PD patients receiving levodopa had 10-20 fold higher L-DOPA levels and about 100 fold higher levels of 3-OMD than age-matched controls or PD not receiving L-DOPA. DOPAC levels were not different among controls and subgroups of PD. HVA levels were significantly lower in non-DOPA-treated PD. Ratios of DOPAC/DOPA or HVA/DOPA were much lower in levodopa-treated patients, not distinguishing dyskinetic (N=6) from non-dyskinetic PD patients (N=5). More patients need to be included. Tryptophan/kynurenine metabolites will be analysed using LC coupled to mass spectrometry (MS).
OriginalsprogEngelsk
Publikationsdato3. jul. 2016
StatusUdgivet - 3. jul. 2016
Begivenhed10th FENS Forum of Neuroscience - København, Danmark
Varighed: 2. jul. 20166. jul. 2016
http://forum2016.fens.org/

Konference

Konference10th FENS Forum of Neuroscience
LandDanmark
ByKøbenhavn
Periode02/07/201606/07/2016
Internetadresse

Citer dette

Dammann Andersen, A., Binzer, M., Stenager, E., Blaabjerg, M., Havelund, J. F., Færgeman, N. J., & Gramsbergen, J. B. (2016). Cerebrospinal fluid levels of catecholamine metabolites in Parkinson’s disease and L-DOPA-induced dyskinesia. Poster session præsenteret på 10th FENS Forum of Neuroscience, København, Danmark.
@conference{5d0a3bc2ffae4061a967f3171f809718,
title = "Cerebrospinal fluid levels of catecholamine metabolites in Parkinson’s disease and L-DOPA-induced dyskinesia",
abstract = "Levodopa (L-DOPA) is effective in the symptomatic treatment of Parkinson’s disease (PD), but chronic use is associated with L-DOPA-induced dyskinesia (LID). In the 6-hydroxydopamine rat model of PD, L-DOPA treatment increases dopamine, its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), as well as 3-O-methyl-DOPA (3-OMD) and tyrosine in the striatum. These changes are most pronounced in dyskinetic rats .(Poster Jesper Christensen, FENS-3253).Aim: Investigating whether tyrosine/dopamine and tryptophan/kynurenine metabolites are altered in LID compared to non-dyskinetic PD patients and controls.Method: Cerebrospinal fluid (CSF) of 6 age-matched controls and 16 PD patients, (11 receiving levodopa, 6 dyskinetic and 6 not receiving levodopa), was analysed for catecholamines and metabolites by HPLC with electrochemical detection. Samples were collected after overnight fasting and 1 hour after intake of medication. Results and conclusion: PD patients receiving levodopa had 10-20 fold higher L-DOPA levels and about 100 fold higher levels of 3-OMD than age-matched controls or PD not receiving L-DOPA. DOPAC levels were not different among controls and subgroups of PD. HVA levels were significantly lower in non-DOPA-treated PD. Ratios of DOPAC/DOPA or HVA/DOPA were much lower in levodopa-treated patients, not distinguishing dyskinetic (N=6) from non-dyskinetic PD patients (N=5). More patients need to be included. Tryptophan/kynurenine metabolites will be analysed using LC coupled to mass spectrometry (MS).",
author = "{Dammann Andersen}, Andreas and Michael Binzer and Egon Stenager and Morten Blaabjerg and Havelund, {Jesper Foged} and F{\ae}rgeman, {Nils J.} and Gramsbergen, {Jan Bert}",
year = "2016",
month = "7",
day = "3",
language = "English",
note = "null ; Conference date: 02-07-2016 Through 06-07-2016",
url = "http://forum2016.fens.org/",

}

Dammann Andersen, A, Binzer, M, Stenager, E, Blaabjerg, M, Havelund, JF, Færgeman, NJ & Gramsbergen, JB 2016, 'Cerebrospinal fluid levels of catecholamine metabolites in Parkinson’s disease and L-DOPA-induced dyskinesia' 10th FENS Forum of Neuroscience, København, Danmark, 02/07/2016 - 06/07/2016, .

Cerebrospinal fluid levels of catecholamine metabolites in Parkinson’s disease and L-DOPA-induced dyskinesia. / Dammann Andersen, Andreas; Binzer, Michael; Stenager, Egon; Blaabjerg, Morten; Havelund, Jesper Foged; Færgeman, Nils J.; Gramsbergen, Jan Bert.

2016. Poster session præsenteret på 10th FENS Forum of Neuroscience, København, Danmark.

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskning

TY - CONF

T1 - Cerebrospinal fluid levels of catecholamine metabolites in Parkinson’s disease and L-DOPA-induced dyskinesia

AU - Dammann Andersen, Andreas

AU - Binzer, Michael

AU - Stenager, Egon

AU - Blaabjerg, Morten

AU - Havelund, Jesper Foged

AU - Færgeman, Nils J.

AU - Gramsbergen, Jan Bert

PY - 2016/7/3

Y1 - 2016/7/3

N2 - Levodopa (L-DOPA) is effective in the symptomatic treatment of Parkinson’s disease (PD), but chronic use is associated with L-DOPA-induced dyskinesia (LID). In the 6-hydroxydopamine rat model of PD, L-DOPA treatment increases dopamine, its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), as well as 3-O-methyl-DOPA (3-OMD) and tyrosine in the striatum. These changes are most pronounced in dyskinetic rats .(Poster Jesper Christensen, FENS-3253).Aim: Investigating whether tyrosine/dopamine and tryptophan/kynurenine metabolites are altered in LID compared to non-dyskinetic PD patients and controls.Method: Cerebrospinal fluid (CSF) of 6 age-matched controls and 16 PD patients, (11 receiving levodopa, 6 dyskinetic and 6 not receiving levodopa), was analysed for catecholamines and metabolites by HPLC with electrochemical detection. Samples were collected after overnight fasting and 1 hour after intake of medication. Results and conclusion: PD patients receiving levodopa had 10-20 fold higher L-DOPA levels and about 100 fold higher levels of 3-OMD than age-matched controls or PD not receiving L-DOPA. DOPAC levels were not different among controls and subgroups of PD. HVA levels were significantly lower in non-DOPA-treated PD. Ratios of DOPAC/DOPA or HVA/DOPA were much lower in levodopa-treated patients, not distinguishing dyskinetic (N=6) from non-dyskinetic PD patients (N=5). More patients need to be included. Tryptophan/kynurenine metabolites will be analysed using LC coupled to mass spectrometry (MS).

AB - Levodopa (L-DOPA) is effective in the symptomatic treatment of Parkinson’s disease (PD), but chronic use is associated with L-DOPA-induced dyskinesia (LID). In the 6-hydroxydopamine rat model of PD, L-DOPA treatment increases dopamine, its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), as well as 3-O-methyl-DOPA (3-OMD) and tyrosine in the striatum. These changes are most pronounced in dyskinetic rats .(Poster Jesper Christensen, FENS-3253).Aim: Investigating whether tyrosine/dopamine and tryptophan/kynurenine metabolites are altered in LID compared to non-dyskinetic PD patients and controls.Method: Cerebrospinal fluid (CSF) of 6 age-matched controls and 16 PD patients, (11 receiving levodopa, 6 dyskinetic and 6 not receiving levodopa), was analysed for catecholamines and metabolites by HPLC with electrochemical detection. Samples were collected after overnight fasting and 1 hour after intake of medication. Results and conclusion: PD patients receiving levodopa had 10-20 fold higher L-DOPA levels and about 100 fold higher levels of 3-OMD than age-matched controls or PD not receiving L-DOPA. DOPAC levels were not different among controls and subgroups of PD. HVA levels were significantly lower in non-DOPA-treated PD. Ratios of DOPAC/DOPA or HVA/DOPA were much lower in levodopa-treated patients, not distinguishing dyskinetic (N=6) from non-dyskinetic PD patients (N=5). More patients need to be included. Tryptophan/kynurenine metabolites will be analysed using LC coupled to mass spectrometry (MS).

M3 - Poster

ER -

Dammann Andersen A, Binzer M, Stenager E, Blaabjerg M, Havelund JF, Færgeman NJ et al. Cerebrospinal fluid levels of catecholamine metabolites in Parkinson’s disease and L-DOPA-induced dyskinesia. 2016. Poster session præsenteret på 10th FENS Forum of Neuroscience, København, Danmark.